Ha Tay Pharmaceutical JSC

HNX:DHT Stock Report

Market Cap: ₫7.9t

Ha Tay Pharmaceutical JSC Past Earnings Performance

Past criteria checks 2/6

Ha Tay Pharmaceutical JSC has been growing earnings at an average annual rate of 1.1%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been declining at an average rate of 0.7% per year. Ha Tay Pharmaceutical JSC's return on equity is 6.6%, and it has net margins of 3.4%.

Key information

1.1%

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth rate-0.7%
Return on equity6.6%
Net Margin3.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ha Tay Pharmaceutical JSC makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

HNX:DHT Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,952,46466,840120,5470
31 Mar 241,975,88475,948112,3310
31 Dec 231,999,30485,056104,1150
30 Sep 232,059,424104,45891,4050
31 Mar 231,928,912102,90888,3060
31 Dec 221,837,39595,21184,8060
30 Sep 221,749,38579,13993,0340
30 Jun 221,582,89064,97188,8440
31 Mar 221,637,14365,70392,4200
31 Dec 211,609,36467,94691,9530
30 Sep 211,781,91172,148102,8300
30 Jun 211,929,21882,433104,4180
31 Mar 211,867,49281,610109,6740
31 Dec 202,006,47592,047129,6330
30 Sep 201,936,71389,424138,3460
30 Jun 202,053,24086,717159,5610
31 Mar 202,159,85193,991165,2550
31 Dec 192,042,23586,233153,2410
30 Sep 191,916,67289,508152,6970
30 Jun 191,842,79844,570145,0410
31 Mar 191,723,27085,409145,4500
31 Dec 181,705,34581,080152,8480
30 Sep 181,657,79486,566143,1740
30 Jun 181,582,94682,939143,2380
31 Mar 181,531,63077,538141,1180
31 Dec 171,480,31572,137138,9990
30 Sep 171,416,99971,387128,6360
31 Mar 171,264,79359,468118,4330
31 Dec 161,205,44153,798114,8350
30 Sep 161,105,29537,833116,9370
31 Mar 16999,55135,590109,0210
31 Dec 15940,57234,354101,0380
30 Sep 15907,66925,444100,6940
30 Jun 15852,25226,25299,0700
31 Mar 15820,66227,37092,0030
31 Dec 14820,05426,29891,7560
30 Sep 14821,57336,76985,9790
30 Jun 14770,58920,95482,6630
31 Mar 14788,28129,55886,5520
01 Jan 14742,98226,76180,0990

Quality Earnings: DHT has high quality earnings.

Growing Profit Margin: DHT's current net profit margins (3.4%) are lower than last year (5.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DHT's earnings have grown by 1.1% per year over the past 5 years.

Accelerating Growth: DHT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DHT had negative earnings growth (-35.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13%).

Return on Equity

High ROE: DHT's Return on Equity (6.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 04:43
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ha Tay Pharmaceutical JSC is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution